ArticleAnnals of surgical oncology2026

Adjuvant Immunotherapy for High-Risk Stage II Melanoma: Real-World Utilization and Associated Overall Survival.

Mohammad Saad Farooq et al.PubMed ↗Publisher ↗

No numbers read from the abstract.